Microchip Technology (MCHP)
NASDAQInformation TechnologySemiconductorsSnapshot 2026-10-29
$77.34-4.66%
Close 2026-10-30 · 1-day change
NASDAQInformation TechnologySemiconductorsSnapshot 2026-10-29
Research Workspace
Put MCHP beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Semiconductors is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is accelerating — up about 21% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 2% a day.
View RiskHealthy across the board
MCHP’s earnings growth is the core case, with revenue growth accelerating across recent reported quarters. Revenue grew 38% year over year in Q1 FY2027, and non-GAAP earnings beat consensus. MCHP trades at 41× P/E versus a 56× peer median. The price reflects less growth than our forecast. A 16% next-quarter miss probability and Mania conditions leave room for disappointment. Peer multiples imply a price about 4% above where it trades; our read remains intact. This read is provisional.
Trailing returns as of 2026-10-30. MCHP is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 26 analysts currently covering MCHP (as of Oct 2026).
Based on 4 Wall Street analysts offering 12-month price targets for MCHP in the last 4 months.
Continue this research
Compare MCHP with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| MCHP Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Semiconductors — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put MCHP next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Drive revenue growth with strong bookings and demand recovery
Q4 beat and strong guidance indicate demand recovery.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $77.34
The last 12 months of price, then the range of analyst 12-month targets from today’s $77.34.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Revenue growth to $1.455 billion in 2026-Q4
Significant revenue growth supports future guidance for 2026-Q4.
Advances: Drive revenue growth with strong bookings and demand recovery
Strong Q1 results indicate robust demand recovery.
Threatens: Drive revenue growth with strong bookings and demand recovery
Inventory concerns may hinder revenue growth.
Advances: Drive revenue growth with strong bookings and demand recovery
Earnings call highlights strong bookings and demand recovery.
Advances: Drive revenue growth with strong bookings and demand recovery
Sales growth supports revenue growth objective.
Advances: Revenue growth to $1.455 billion in 2026-Q4
Better-than-expected sales support revenue growth objective.
New product aligns with growth objectives and enhances market position.